General Description

Protalix BioTherapeutics

Youtube Subscribe

Ticker: PLX

Sector: Biotechnology

Protalix BioTherapeutics (PLX) reported earnings of -$0.04 per share, beating the Zacks Consensus Estimate of $-0.07 per share. Long-term predictions suggest that the price.

Extended Summary

Protalix BioTherapeutics

Protalix BioTherapeutics (PLX) reported earnings of -$0.04 per share, beating the Zacks Consensus Estimate of $-0.07 per share. Protalix Biotherapeutics is leading the therapeutics market with its Fabry Disease drug candidates in the most advanced stage of clinical development. According to our current PLX stock forecast, the value of ProtalIX Biotheraputics shares will drop by -7.20% and reach $ 1.512707 per share by 2023. Protalix Biotherapeutics stock performed -45.37% worse in the last year and -24.94% worse than Bitcoin. Long-term predictions suggest that the price of the PLX stock will not reach $500.

Related Results

December 10, 2023 12:19 (London Time)